Moreover, considering the rich mutational landscape of AML, venetoclax is currently under investigation combined with targeted options, specifically with FLT-3 inhibitors (e.g., gilderitinib) and IDH1 inhibitors (e.g., ivosidenib) [74,75]. Here, IDH1 is linked to acute myeloid leukemia.